Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $10.2 million.

  • Roivant Sciences' Other Accumulated Expenses fell 8084.17% to $10.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.2 million, marking a year-over-year decrease of 8084.17%. This contributed to the annual value of $1.6 million for FY2025, which is 9579.97% down from last year.
  • As of Q4 2025, Roivant Sciences' Other Accumulated Expenses stood at $10.2 million, which was down 8084.17% from $1.5 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Other Accumulated Expenses registered a high of $76.3 million during Q1 2023, and its lowest value of $1.5 million during Q3 2025.
  • In the last 5 years, Roivant Sciences' Other Accumulated Expenses had a median value of $45.0 million in 2023 and averaged $36.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 194032.06% in 2022, then tumbled by 9737.83% in 2025.
  • Roivant Sciences' Other Accumulated Expenses (Quarter) stood at $12.4 million in 2021, then surged by 352.97% to $56.3 million in 2022, then dropped by 22.55% to $43.6 million in 2023, then rose by 22.55% to $53.5 million in 2024, then plummeted by 80.84% to $10.2 million in 2025.
  • Its Other Accumulated Expenses was $10.2 million in Q4 2025, compared to $1.5 million in Q3 2025 and $49.8 million in Q2 2025.